Read this before buying Ramsay Health Care shares for its dividend

Ramsay Health Care Limited Fully Paid Ord. Shrs (ASX:RHC ) shares go ex-dividend on Wednesday March 6, 2019. Here's what you need to know.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited Fully Paid Ord. Shrs (ASX: RHC) share price fell 1.32% on the ASX today to close at $63.03.

If you've been thinking of buying shares in the global hospital group for its growing, fully franked divided, there are a few things you need to know today.

The first is that shares will go ex-dividend on Wednesday, March 6, 2019.  The 'ex-date' is when the shares start selling without the value of its next dividend payment so an investor needs to own the shares before the ex-date to receive the dividend. The dividend will then be paid on Friday, March 29, 2019.

What is Ramsay Health Care's dividend yield?

At its recent half-year results, Ramsay declared a dividend of 60 cents per share for the half year. This was up 4.3% on the same period in 2018 and at the current share price of $63 per share the company offers a trailing dividend yield of 2.3%, fully franked.

Is the dividend sustainable going forward?

This is a great question to ask before buying any company for its dividend.

At the company's half-year update last week Ramsay presented Net profit after tax (NPAT) of $274 million for the six months to 31 December 2018, up 1.1% on the same period in 2017.

Pleasingly revenue lifted 16% and cash flows from operations lifted 6.5% which is a positive sign for sustaining dividends.

Ramsay has a strong history of earnings and dividend growth and looking forward the group is expecting to achieve its guidance of 'Core' earnings per share (EPS) growth of up to 2% for the full financial year.

Foolish takeaway

I think Ramsay Health Care will be a clear beneficiary of the long-term trend of increasing healthcare expenditure and although its current yield of 2.3% is not earth-shattering, the long-term prospects for increasing distributions to investors would be worth short-listing to my dividend watch-list.

However, there are also several other companies going ex-dividend on 06 March to consider, including:

  • FlexiGroup Limited (ASX: FXL)
  • Event Hospitality and Entertainment Ltd (ASX: EVT)
  • Hansen Technologies Limited (ASX: HSN)

Regan Pearson has no position in any of the stocks mentioned. You can follow him on Twitter @Regan_Invests. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Hansen Technologies. The Motley Fool Australia has recommended FlexiGroup Limited and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »